WW — WW International, Inc.

WW (WeightWatchers) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $163 million, down 12% year-over-year.
• Adjusted EBITDA: $18 million, with an adjusted EBITDA margin of 11.1%.
• Adjusted Gross Margin: 74.4%, slightly down from Q3.
• End-of-Period Clinical Subscribers: 130,000, with expectations to reach approximately 200,000 by the end of Q1 2026, indicating nearly 100% year-over-year growth.
• End-of-Period Behavioral Subscribers: 2.6 million, down 26% year-over-year.
• Average Revenue Per User (ARPU): Increased 8% year-over-year to $18.73, with clinical ARPU over 4x higher than behavioral ARPU.

2. Strategic Updates and Business Highlights

• Successfully emerged from Chapter 11, reducing debt by over $1.1 billion, allowing for reinvestment in growth.
• Launched new offerings including the GLP-1 Success program and Med+, integrating clinical care with behavioral support.
• Marketing efforts have led to a significant increase in brand awareness and member acquisition, particularly in the Med+ segment, where 50% of new members are first-time WeightWatchers users.
• Focus on modernizing technology and enhancing member experience through a new mobile app and AI tools.
• Continued emphasis on a holistic approach to weight health, integrating medication access with behavioral support.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected to be between $620 million and $635 million.
• Adjusted EBITDA Guidance: Anticipated to be between $105 million and $115 million.
• Expectation of continued growth in clinical subscribers, with a shift in marketing focus to support both clinical and behavioral offerings.
• Anticipate challenges in the behavioral segment due to ongoing secular headwinds.

4. Bad News, Challenges, or Points of Concern

• Behavioral business facing significant headwinds, with a 26% decline in subscribers year-over-year.
• Core segment under pressure due to strategic focus on Med+, leading to customer acquisition challenges.
• The company must navigate the transition from a legacy behavioral model to a more integrated clinical approach, which may take time and careful management.
• Potential risks associated with the growing adoption of GLP-1 medications, which could disrupt traditional behavioral offerings.

5. Notable Q&A Insights

• Management noted increasing consumer interest in GLP-1 medications, with a focus on integrating these into their offerings rather than shifting to a prescription-only model.
• Approximately 50% of new Med+ members are new to the WeightWatchers brand, indicating successful brand repositioning efforts.
• The company is seeing a trend towards longer-term contracts in both clinical and behavioral segments, which is a positive sign for future revenue stability.
• The B2B initiative is gaining traction, with plans to expand partnerships and offerings, although it remains a small percentage of total revenue.

Overall, WeightWatchers is positioning itself for growth in a rapidly changing weight management landscape, leveraging its brand and new clinical offerings while facing challenges in its traditional business model.